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↑ What is "already known" in this topic: {#box1}
========================================

*Acinetobacter baumannii* is reported as one of the dreadful and emerging nosocomial pathogens by World Health Organization (WHO). In recent years, serious complications are encountered by *A. baumannii* strains due to its multi-drug resistant property. Routine susceptibility pattern incorporates only few antibiotics for profiling which needs to be elaborated.

→ What this article adds: {#box2}
=========================

The incidence of MDR and XDR strains of PCR confirmed isolates of *A. baumannii* was high when subjected to antibiotic profiling for the frequency of resistance against different classes of antibiotics as per CLSI guidelines. Further, the study emphasizes the necessity of periodical antibiotic surveillance to curb the menace of drug resistance among *A. baumannii* strains.

Introduction {#s1}
============

Emergence of *A. baumannii* (Ab) as a major cause of hospital-acquired infections is mainly due to its propensity of accumulating and exhibiting antimicrobial drug re-sistance and thus large outbreaks with great challenges for the treating physicians ([@R1]). MDR-Ab refers to strains that exhibit resistance to more than three or more antimicrobi-al drug classes ([@R2]). XDR-Ab refers to *A. baumannii* strains resistant to all but two drug classes ([@R3]). Pan-drug re-sistance refers to resistance exhibited by the strains to all drug clas-ses ([@R4]), and emergence of pan-resistant A. baumann ii isolates was reported including the isolates that were re-sistant to carbapenems, colistin, and polymyxins ([@R5], [@R6]). This alarming scenario is mainly due to multiple mecha-nisms of drug resistance exhibited by *A. baumannii* viz., impermeable outer membrane, production of enzymes such as AmpC-β lactamase ([@R7]), class D OXA -- type β lactamase ([@R8]), and class D metallo β lactamase ([@R9]) that allows resistance to carbapenems, porin channel altera-tion as well as efflux pumps and other genetic factors that may lead to resistance to fluoroquinolones ([@R10]). Lack of routine assessment of *A. baumannii* incidence and period-ical antibiotic surveillance has transformed *A. baumannii* as one of the emerging UTI pathogens in south India.

Mounting evidence is available towards the emergence of MDR, XDR and pan-DR *A. baumannii* strains globally and also in India. In recent decades MDR *A. baumannii* has been reported in hospitalized older adults with a lengthier hospital stay, especially in patients with invasive devices and/or underlying comorbidities ([@R11]). Increasing reports of MDR-Ab globally and its rapid spread is of im-portance in the national scale ([@R12], [@R13]). Information re-garding the prevalence and pattern of resistance in *A. baumannii* through CLSI based antibiotic surveillance is the need of the hour to combat and control the resistance pattern in *A. baumannii* ([@R14]).

Clinical laboratory and Standards Institute ([@R15]) rec-ommends the application of Group A (Routine/primary testing and report), Group B (Optional testing) and Group U (Supplementary for urine samples) for antibiotic surveil-lance testing and reporting in the diagnostic laboratory. Most of the MDR and XDR studies among *A. baumannii* do not incorporate these criteria and there is a lacuna for the same data in recent years. This present investigation is thus designed to investigate a CLSI based antibiogram profile of *A. baumannii* characterized from the urine samples of the patients with severe urinary tract infections \[UTI\], to detect the MDR and XDR *A. baumannii*.

Methods {#s2}
=======

Study design {#s2-0-1}
------------

This prospective, single-centric study utilized a total of 73 consecutive, non-repetitive *A. baumannii* strains for the antibiogram profile analysis which were isolated and collected during a period of 12 months (2014-2015) at a private hospital, from the urine samples of the patients with severe urinary tract infections \[UTI\] (N=1000). The sample size was estimated using the formula n= (Z1-α)2 (P (1− P)/D2) ([@R16]), with an approximate prevalence of 50%, confidence interval 95%, precision 5%, and the power was set as 80%. As an inclusion criteria, patients were selected based on the UTI manifested with one or more of the following symptoms such as frequency and urgency of urination, suprapubic discomfort, dysuria, and flank pain, without prior administration of antibiotics. All the other strains isolated were excluded from the study. Random sampling technique regardless of demographic data like age, clinical data, period of hospital stay etc., was used. Proper ethical clearance and consents were obtained as per standard guidelines ([@R17]).

Phenotypic and genotypic identification of the strains {#s2-0-2}
------------------------------------------------------

Preliminary identification of the strains was done by colony morphology, gram stain, positive citrate, negative oxidase, and urease tests. All the strains were phenotypically characterized by simplified assays as recommended by Prashanth et al. 2000 ([@R18]). The strains were also further genotypically confirmed by extracting the *A. baumannii* DNA by QIAamp DNA mini kit and by further DNA amplification by PCR as per Elhabibi and Ramzy (2012) ([@R19]) using the forward primer as F'-5'- AGAGTTTGATCCTGGCTCAG-3' and reverse primer as R'-5'-TACCAGGGTATCTAATCCTGTT-3' \[Eurofins Genomic India Pvt Ltd, Bangalore\]. The amplicon size was 750 bp.

Antibiogram profiling {#s2-0-3}
---------------------

Antimicrobial susceptibility testing of the *A. baumannii* isolates was performed by Kirby Bauer method as recommended by Clinical Laboratory and Standards Institute (CLSI, 2012). The antibiotic discs were obtained from Hi-Media laboratories, Mumbai. As per CLSI, 2012, group A primary testing, reporting and recording was done using the following antibiotics viz., Ampicillin-sulbactam (10µg/10µg), ceftazidime (30 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), Doripenem (10 µg), imipenem (10 µg), meropenem (10 µg), gentamicin (10 µg) and tobramycin (10 µg). As an optional primary test and for the study purpose, group B antibiotics such as amikacin (30 µg), piperacillin-tazobactam (100 µg/10 µg), cefepime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), doxycycline (30 µg), minocycline (30 µg), trimethoprim--sulphamethoxazole (1.25 µg/23.75 µg) were also included. Group U supplementary antibiotic tetracycline (30 µg) was also included as the study involves the strains isolated from urine specimens. Colistin and tigecycline were also included for the detection of pan-DR *A. baumannii* isolates and was assayed by microbroth dilution method.

Briefly, a suspension of *A. baumannii* isolates was prepared equivalent to 0.5 McFarland standards and was made as lawn cultures onto sterile Mueller Hinton agar plates. Using sterile forceps, the antibiotic discs were placed on the surface of the plates and were incubated at 37°C for 18-24 hrs. Criteria for the interpretation of the zone diameter (rounded to nearest mm) for susceptible, intermediate and resistance was done and recorded as per CLSI guidelines, 2012. The antibiotic potency of the disks was standardized against the reference strains *Escherichia coli* (ATCC 25922), *Staphylococcus aureus* (ATCC 25923) and *Pseudomonas aeruginosa* (ATCC 27853). Multidrug-resistant (MDR), extremely drug resistant (XDR) and pan drug\--resistant (PDR) group of *A. baumannii* were defined according to the international expert proposal for interim standard definitions for acquired resistance ([@R20]).

Results {#s3}
=======

Group A antibiogram profile based on CLSI breakpoints of the antimicrobial agents used for the study showed highest non-susceptibility (n=73 (100%)) to ampicillin-sulbactam, ceftazidime and imipenem by *A. baumannii* isolates ([Fig. 1](#F1){ref-type="fig"}). This is followed by 82.19%, 79.45%, 67.12%, 61.64%, 56.16% and 49.31% non-susceptible isolates against ciprofloxacin, gentamicin, meropenem, doripenem, tobramycin, and levofloxacin respectively. The highest intermediate resistance was recorded by 30.13% (n=22) against levofloxacin. However, highest susceptibility was observed in 30.13% against tobramycin followed by 20.54% against levofloxacin ([Table 1](#T1){ref-type="table"}).

###### Group A, Group B and Group U antibiogram susceptibility profile of *A. baumannii* isolated from urine samples \[as per CLSI recommendations, 2012\]

  -------------------------------------------------------- ---------------------- ------------------------- --------------------------------------------------------- ------------------------------------------------- ------------ ------------ ------------ ------------
  Suggested groupings M02 & M07 \[Table 1A, CLSI, 2012\]   Antimicrobial agent    Disc con-tent \[in µg\]   Zone Diameter Interpretive Crite-ria (nearest whole mm)   *A. baumannii* antibiogram pattern \[n=73 (%)\]                                          
  S                                                        I                      R                         S                                                         I                                                 R                                      
  Group A primary testing and report                       Ampicillin-sulbactam   10/10                     ≥15                                                       12-14                                             ≤11          0 (0)        0 (0)        73 (100)
  Ceftazidime                                              30                     ≥18                       15-17                                                     ≤14                                               0 (0)        0 (0)        73 (100)     
  Ciprofloxacin                                            5                      ≥21                       16-20                                                     ≤15                                               5 (6.84)     8 (10.95)    60 (82.19)   
  Levofloxacin                                             5                      ≥17                       14-16                                                     ≤13                                               15 (20.54)   22 (30.13)   36 (49.31)   
  Doripenem                                                10                     ≥18                       15-17                                                     ≤14                                               11 (15.06)   17 (23.28)   45 (61.64)   
  Imipenem                                                 10                     ≥22                       19-21                                                     ≤18                                               0 (0)        0 (0)        73 (100)     
  Meropenem                                                10                     ≥18                       15-17                                                     ≤14                                               10 (13.69)   14 (19.17)   49 (67.12)   
  Gentamicin                                               10                     ≥15                       13-14                                                     ≤12                                               6 (8.21)     9 (12.32)    58 (79.45)   
  Tobramycin                                               10                     ≥15                       13-14                                                     ≤12                                               22 (30.13)   10 (13.69)   41 (56.16)   
  Group B optional primary testing                         Amikacin               30                        ≥17                                                       15-16                                             ≤14          0 (0)        0 (0)        73 (100)
  Piperacillin-tazobactam                                  100/10                 ≥21                       18-20                                                     ≤17                                               0 (0)        0 (0)        73 (100)     
  Cefepime                                                 30                     ≥18                       15-17                                                     ≤14                                               0 (0)        0 (0)        73 (100)     
  Cefotaxime                                               30                     ≥23                       15-22                                                     ≤14                                               0 (0)        0 (0)        73 (100)     
  Ceftriaxone                                              30                     ≥21                       14-20                                                     ≤13                                               6 (8.2)      0 (0)        67 (91.78)   
  Doxycycline                                              30                     ≥13                       10-12                                                     ≤9                                                41 (56.16)   18 (24.65)   14 (19.71)   
  Minocycline                                              30                     ≥16                       13-15                                                     ≤12                                               56 (76.71)   12 (16.43)   5 (6.84)     
  Trimethoprim -- suphamethoxa-zole                        1.25 / 23.75           ≥16                       11-15                                                     ≤10                                               4 (5.47)     2 (2.73)     67 (91.78)   
  Group U supplementary for urine                          Tetracycline           30                        ≥15                                                       12-14                                             ≤11          0            17 (23.28)   56 (76.71)
  -------------------------------------------------------- ---------------------- ------------------------- --------------------------------------------------------- ------------------------------------------------- ------------ ------------ ------------ ------------
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Group B antibiogram profile showed 100% non-susceptibility by n=73 isolates of *A. baumannii* to piperacillin-tazobactam and to amikacin. Similarly, none of them were susceptible to cefepime and cefotaxime, with 91.78% (n=67) of isolates resistant to ceftriaxone with 8.2% (n=6) showing susceptibility for the same. Among the cyclines, 19.71% and 6.84% of isolates were resistant to doxycycline and minocycline respectively. However, 76.71% of the isolates were susceptible to minocycline followed by 56.16% susceptibility against doxycycline ([Table 1](#T1){ref-type="table"} & [Fig. 1](#F1){ref-type="fig"}). Group U supplementary antibiotic testing for urine specimens with tetracycline as per CLSI recommendations which was performed in the study recorded 23.28% intermediate and 76.71% of resistance by the tested *A. baumannii* isolates with n=73 nonsusceptible isolates against the same.

Among the different classes of drugs tested, highest non-susceptibility of 100% was observed against β-lactam inhibitors, followed by cephems \[ceftazidime, cefepime, cefotaxime,, and ceftriaxone\] and folate pathway inhibitors \[Trimethoprim sulphamethoxazole\] each group exhibiting 91.78% non-susceptibility. This was followed by aminoglycosides (53.42%), carbapenems (50.68%) and fluoroquinolones (45.20%). The least susceptibility was observed with the cycline group of drugs ([Fig. 2](#F2){ref-type="fig"}).
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According to the interim standard definitions for acquired resistance as recommended by Magiorakos et al. 2011 ([@R20]), the present investigation has observed the frequency of MDR-Ab in 71.23% (n=52) of isolates and XDR-Ab in 39.72% (n=29) based on the antibiogram profile against different classes of antibiotics ([Fig. 3](#F3){ref-type="fig"}). None of the strains were categorized as pan-DR *A. baumannii* as they showed 100% susceptibility to colistin and tigecycline with MIC≤ 2 µg/ml and ≤ 0.1 µg/ml respectively.
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Discussion {#s4}
==========

*A. baumannii* is a ubiquitous opportunistic nosocomial pathogen and in recent decades has shown more complications in hospitalized patients. In the present investigation, special concern to confirm all the strains by PCR with an amplicon size of 750 bp was made prior subjecting the strains for antibiogram profiling, as phenotypic characterization is not reliable. In UTI cases, *A. baumannii* is a serious concern due to the increasing rate of resistance to multiple classes of antibiotics ([@R21]) and studies show that this resistance is expanding among hospitalized patients ([@R22]). *A. baumannii* being an explorer of intrinsic resistance by nature and its unusual and unpredictable susceptibility patterns ([@R23]) it is of paramount importance to monitor the incidence of MDR-Ab, XDR-Ab, and pan-DR-Ab and to limit its spread among hospitalized patients. Increasing reports of MDR-Ab is not unusual ([@R24]). Many reports are available from different parts of the world and appear to be at a startling rate posing a serious threat to the community ([@R25]-[@R28]). In spite of many available data of MDR-Ab, the prevalence rate of the same in the past two years is still non-convincing. In this view, the present findings recorded the overall relative frequency of the incidence of MDR and XDR *A. baumannii* among the study population (N=1000) with UTI during the period of 2014-2015.

Among the cephems tested, highest non-susceptibility (100% (n=73)) to ceftazidime, cefotaxime, and cefepime was observed which correlated with the earlier studies ([@R29], [@R30]). In addition, 91.78% non-susceptibility exhibited by the *A.baumannii* against ceftriaxone in the present investigation is consistent with the earlier studies ([@R9]). The resistance against cephalosporins might be due to the presence of plasmid-mediated *blaTEM, blaSHV*, and *blaCTX-M* as detected in our earlier studies ([@R31]). Carbapenems such as imipenem have recorded 100% non-susceptibility which has correlated with earlier studies ([@R32]). This is followed by meropenem and doripenem suggesting that carbapenem-resistant strains were frequently associated with considerable mortality and hospital costs in nosocomial infections ([@R33], [@R34]). Also, in correlation with the present investigation high frequency of carbapenem resistance is recorded among clinical isolates of *A.baumannii* ([@R35]) due to the plasmid-mediated genetic determinants viz., *blaIMP, blaVIM* and *blaGIM* ([@R36]). However, lower resistance profile against carbapenems was also recorded ([@R37]).

High level of aminoglycoside resistance was also recorded in the present study. In the routine treatment, aminoglycosides are often used in combination with broad spectrum β-lactams to treat gram-negative bacterial infections ([@R38]). In recent years, resistance to amikacin and gentamicin is considerably higher resulting as a serious problem in combination therapy ([@R39]). The present investigation also reports the prevalence of aminoglycoside-resistant strains of *A. baumannii* among 53.42% of isolates posing an alarming scenario. Amikacin showed 100% non-susceptibility followed by gentamicin (79.45%) and tobramycin (56.16%). Among the fluoroquinolones, ciprofloxacin and levofloxacin resistance exhibited by 82.19% and 49.31% isolates was comparable with the earlier reports ([@R40]).

In the present scenario of the emergence of MDR-Ab nosocomial infections, application of older antibiotics like tetracycline and related cyclines (doxycycline and minocycline) has been highly reduced thus lacking improper data against the resistance exhibited by the same. The frequency of tetracycline resistance exhibited by *A. baumannii* was relatively high ([@R41]), which correlates with the 76.71%, 19.71% and 6.84% of resistance against tetracycline, doxycycline, and minocycline respectively observed in the present study and might be due to the plasmid-mediated tetA and tet B genetic determinants ([@R42]).

Intrinsic resistance seems to play a significant role in MDR-Ab emergence and particularly with trimethoprim resistance. In the present investigation, as the strains were isolated from urine specimen, the application of trimethoprim -- sulphamethoxazole (TMP-SMX) is considered as essential and is routinely included in the therapeutic regimen ([@R43]). In an earlier study ([@R44]), 70.6% of *A. baumannii* was reported to exhibit resistance to TMP-SMX which correlates with the high non-susceptibility (91.78%) exhibited by the *A. baumannii* isolates in the present investigation. 100% of non-susceptibility against the β lactams inhibitors such as ampicillin-sulbactam and piperacillin-tazobactam might be due to intrinsic resistance exhibited by the *A. baumannii* isolates as reported by Hans et al. 2015 ([@R45]).

The categorization of MDR and XDR in the present study was done as per standard interim protocols as done in earlier studies ([@R46]). *A. baumannii* is considered as MDR-Ab when it exhibits resistance to at least three different classes of antimicrobial agents mainly beta-lactams (third-generation cephalosporins), aminoglycosides, fluoroquinolones and more recently carbapenems ([@R47]-[@R49]). In correlation with this, it was not infrequent in the present investigation 71.23% of the isolates showing multidrug resistance to more than three antimicrobial categories. Similarly, XDR-Ab strains explore resistance to all group of drugs but two. In this concern, the present study has investigated the occurrence of the same in 39.72% of isolates. 4.10% (n=3) was recorded with non-susceptibility against all the tested groups except colistin and tigecycline suggesting the suitability of these drugs in the treatment of *A. baumannii* nosocomial infections ([@R50]).

In addition, the present investigation in an indirect manner portrays about the clinical impact of these routine drugs of choice. 71.23% of MDR-Ab observed in the study suggests the complications of the nosocomial infections that might arise due to these strains. The combination of drugs may not be effective too, as XDR-Ab has also accounted to 39.72% among the tested strains. This emphasizes the need for a vast epidemiological data and also suggests the ecological factors which are responsible for the emergence of these types of resistant strains resulting in complicated urinary tract infections. The study has limited itself to urine samples, but epidemiological studies involving the strains from various clinical samples might give additional information about the prevalence and incidence of resistant strains among *A. baumannii* and a vivid picture about the clinical impact in the administration of these drugs in the treatment of other nosocomial infections.

Conclusion {#s5}
==========

*A. baumannii* strains are posing a serious threat of nosocomial infections, and complications in patient care, the rapid institution of appropriate antimicrobial chemotherapy may be lifesaving. A significant impact on patient care can be achieved only with the rapid assessment and periodical monitoring using antibiotic surveillance as done in the present study. The emergence of MDR and XDR strains of *A. baumannii* is alarming and choosing the correct antibiotic of choice or application of a combination of antibiotics is essential to curb the menace of emerging resistance pattern by *A. baumannii* strains in hospital environment.
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